You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Classic Hodgkin Lymphoma

Showing 1 - 25 of 7,513
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Classic Hodgkin Lymphoma Trial (Concurrent penpulimab and AVD, Sequential penpulimab and AVD)

Not yet recruiting
  • Classic Hodgkin Lymphoma
  • Concurrent penpulimab and AVD
  • Sequential penpulimab and AVD
  • (no location specified)
Jul 10, 2023

Hodgkin Lymphoma Trial in Houston (Brentuximab vedotin, Doxorubicin Hydrochloride, Pembrolizumab)

Not yet recruiting
  • Hodgkin Lymphoma
  • Brentuximab vedotin
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Jun 20, 2023

Safety Issues, Efficacy, Self Trial in Monterrey (low dose nivolumab in combination with AVD)

Recruiting
  • Safety Issues
  • Efficacy, Self
  • low dose nivolumab in combination with AVD
  • Monterrey, Nuevo Leon, Mexico
    Hospital Universitario Dr Jose Eleuterio Gonzalez
Mar 6, 2023

Hodgkin Lymphoma, Classic Hodgkin Lymphoma, Relapsed Classical Hodgkin Lymphoma Trial in Stanford (Magrolimab, Pembrolizumab,

Recruiting
  • Hodgkin Lymphoma
  • +3 more
  • Stanford, California
    Stanford University
Jun 21, 2022

Classic Hodgkin's Lymphoma Trial in Beijing (Sintilimab, Carboplatin, Etoposide)

Recruiting
  • Classic Hodgkin's Lymphoma
  • Sintilimab
  • +4 more
  • Beijing, Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciences
Sep 12, 2022

Hodgkin Lymphoma, Relapsed Hodgkin's Disease, Adult, Refractory Hodgkin Lymphoma Trial in Boston (Nivolumab, Ipilimumab)

Recruiting
  • Hodgkin Lymphoma
  • +2 more
  • Boston, Massachusetts
  • +2 more
Oct 18, 2022

Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma Trial in Duarte (Nivolumab, Oral Azacitidine)

Recruiting
  • Recurrent Classic Hodgkin Lymphoma
  • Refractory Classic Hodgkin Lymphoma
  • Nivolumab
  • Oral Azacitidine
  • Duarte, California
    City of Hope Medical Center
Feb 28, 2022

Recurrent Anaplastic Large Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Classic Hodgkin Lymphoma Trial in

Recruiting
  • Recurrent Anaplastic Large Cell Lymphoma
  • +9 more
  • Anti-CD30/CD16A Monoclonal Antibody AFM13
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 9, 2022

Hodgkin Lymphoma, Adult, Relapse, Refractory Hodgkin Lymphoma Trial in Tianjin (PD-1 inhibitor)

Recruiting
  • Hodgkin Lymphoma, Adult
  • +2 more
  • PD-1 inhibitor
  • Tianjin, Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Dec 14, 2021

Hodgkin Lymphoma, Adult Trial in Beijing (SHR-1210)

Completed
  • Hodgkin Lymphoma, Adult
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Oct 29, 2021

Hodgkin Lymphoma, Peripheral T Cell Lymphoma, Anaplastic Large Cell Lymphoma Trial in United States (brentuximab vedotin)

Terminated
  • Hodgkin Lymphoma
  • +2 more
  • brentuximab vedotin
  • Anaheim, California
  • +18 more
Dec 6, 2022

Head Neck Cancer, Cervical Cancer, Endometrial Cancer Trial (ILB-2109, Toripalimab)

Not yet recruiting
  • Head and Neck Cancer
  • +9 more
  • (no location specified)
Jul 12, 2023

Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma Trial (procedure, drug, biological, radiation, other)

Not yet recruiting
  • Recurrent Classic Hodgkin Lymphoma
  • Refractory Classic Hodgkin Lymphoma
  • Autologous Hematopoietic Stem Cell Transplantation
  • +13 more
  • (no location specified)
Feb 2, 2023

Ann Arbor Stage I Hodgkin Lymphoma, Ann Arbor Stage I Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage I Nodular

Recruiting
  • Ann Arbor Stage I Hodgkin Lymphoma
  • +13 more
  • Birmingham, Alabama
  • +16 more
Nov 23, 2021

Solid Tumor, Classic Hodgkin Lymphoma Trial in China (IMM01, Tislelizumab)

Recruiting
  • Solid Tumor
  • Classic Hodgkin Lymphoma
  • Hangzhou, China
  • +4 more
Apr 18, 2023

Recurrent Classic Hodgkin Lymphoma Trial in Duarte (Brentuximab Vedotin, Nivolumab)

Recruiting
  • Recurrent Classic Hodgkin Lymphoma
  • Brentuximab Vedotin
  • Nivolumab
  • Duarte, California
    City of Hope Medical Center
Feb 16, 2022

Ann Arbor Stage IB Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma, Ann Arbor Stage IIA Hodgkin Lymphoma Trial in United

Active, not recruiting
Has Results
  • Ann Arbor Stage IB Hodgkin Lymphoma
  • +10 more
  • Brentuximab Vedotin
  • Nivolumab
  • Palo Alto, California
  • +8 more
Jul 20, 2022

Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin

Active, not recruiting
  • Adult Lymphocyte Depletion Hodgkin Lymphoma
  • +16 more
  • 6,8-bis(benzylthio)octanoic acid
  • bendamustine hydrochloride
  • Winston-Salem, North Carolina
  • +1 more
Apr 8, 2022

Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic Hodgkin Lymphoma, Recurrent

Not yet recruiting
  • Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
  • +21 more
  • Biopsy
  • +8 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Apr 7, 2023

Classic Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in United States (drug, other,

Active, not recruiting
  • Classic Hodgkin Lymphoma
  • +2 more
  • Brentuximab Vedotin
  • +2 more
  • Duarte, California
  • +5 more
Mar 17, 2022

AIDS-Related Non-Hodgkin Lymphoma, Classic Hodgkin Lymphoma, Clinical Stage III Cutaneous Melanoma AJCC v8 Trial in United

Recruiting
  • AIDS-Related Non-Hodgkin Lymphoma
  • +29 more
  • Laboratory Biomarker Analysis
  • Pembrolizumab
  • Birmingham, Alabama
  • +12 more
Aug 4, 2022

Aggressive Non-Hodgkin Lymphoma, ALK-Positive Large B-Cell Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate

Recruiting
  • Aggressive Non-Hodgkin Lymphoma
  • +8 more
  • Polatuzumab Vedotin
  • +6 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jan 26, 2023

Recurrent ALK Positive Large B-Cell Lymphoma, Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between

Not yet recruiting
  • Recurrent ALK Positive Large B-Cell Lymphoma
  • +28 more
  • Biospecimen Collection
  • +5 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Aug 17, 2022

Aggressive Non-Hodgkin Lymphoma, Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Ann Arbor Stage II

Active, not recruiting
  • Aggressive Non-Hodgkin Lymphoma
  • +13 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Aug 18, 2022

Advanced Malignant Solid Tumor, Anal Carcinoma, HIV Infection Trial in Australia, United States (Ipilimumab, Nivolumab)

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +8 more
  • Ipilimumab
  • Nivolumab
  • La Jolla, California
  • +34 more
Nov 29, 2022